Management of autoimmune skin disorders in the elderly.
Senescence of the skin immunological system may explain why the elderly population has an increased susceptibility to certain autoimmune skin disorders. These disorders are characterised by the production of either antibodies that react with host tissue or immune effector T cells that are autoreactive. Bullous pemphigoid is the most common autoimmune blistering disease in the elderly. Although oral corticosteroids are the best established therapy, high-potency topical corticosteroids are very useful as initial treatment and, in the elderly, should be used instead of oral prednisolone wherever possible. Pemphigus is a chronic blistering disease of which there are two main subtypes: vulgaris and foliaceous. Paraneoplastic pemphigus is a unique clinical, histological and immunologically distinct autoimmune mucocutaneous disease which tends to be relentlessly progressive. Lichen sclerosus presents specific complications and a small but definite increased risk of squamous cell carcinoma in elderly patients. It is important to be aware of practical issues such as the difficulty in applying topical corticosteroids, the mainstay treatment of this condition. Dermatomyositis is an autoimmune systemic disorder where the skin and muscles are the most commonly affected organs. Tumour-associated disease occurs more commonly in elderly patients and has a poorer prognosis. Management of the disease includes sunscreens, topical or systemic corticosteroids, antimalarials, oral immunosuppressants or intravenous immunoglobulins. It is important to bear in mind that old age modifies the management of skin diseases because of physical and social circumstances as well as the unwanted adverse effects of medications. Polypharmacy results in an increased risk of drug interactions and, therefore, drug regimens need to be kept as simple as possible. Drug-induced autoimmune skin eruptions are common amongst the elderly and usually resolve when the offending drug is discontinued.
Loo
Wei Jing
WJ
Department of Dermatology, Addenbrooke's NHS Trust, Cambridge, UK. wjloo@hotmail.com
Burrows
Nigel P
NP
D000305:Adrenal Cortex Hormones / Q000627:therapeutic use*; D000368:Aged; D001327:Autoimmune Diseases / Q000188:drug therapy / Q000276:immunology / Q000503:physiopathology; D003882:Dermatomyositis / Q000503:physiopathology*; D004890:Erythema / Q000139:chemically induced* / Q000276:immunology; D005260:Female; D005853:Geriatrics; D006801:Humans; D018459:Lichen Sclerosus et Atrophicus / Q000276:immunology / Q000473:pathology*; D008297:Male; D008875:Middle Aged; D010391:Pemphigoid, Bullous / Q000188:drug therapy* / Q000276:immunology; D010392:Pemphigus / Q000188:drug therapy* / Q000276:immunology / Q000473:pathology
D000305:Adrenal Cortex Hormones